周姗姗,阳 霞,叶丽好

目的：探讨结肠癌患者腹腔灌注重组改构人肿瘤坏死因子（rmhTNF）的短期安全性。方法：选取2023年9月至2025年4月的结肠癌患者81例，根据治疗方案分成观察组（n=39，根治性手术联合rmhTNF腹腔灌注治疗）和对照组（n=42，仅接受根治性手术治疗），比较两组患者治疗后指标的差异。结果：两组患者在治疗后的体温、胃肠道症状、疼痛、并发症、术后首次排气时间、术后住院时间、舒张压、实验室指标等方面的差异均无统计学意义（p>0.05）。观察组患者的收缩压在首次腹腔灌注rmhTNF后较对照组显著升高（mean difference=9.34，p=0.049）。结论：结肠癌患者腹腔灌注rmhTNF在住院期间是安全的，但需密切监测并采取积极措施以应对可能发生的不良反应。

重组改构人肿瘤坏死因子；腹腔灌注；结肠癌；安全性

[1] BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA:a cancer journal for clinicians,2024,74(3):229-63. [2] 姚宏伟,孙应实,张晓燕,等.结直肠癌多学科综合治疗协作组诊疗模式中国专家共识(2023版)[J].中国实用外科杂志,2024, 44(01):1-16. [3] MARJANEH R M,KHAZAEI M,FERNS G A,et al.The role of microRNAs in 5-FU resistance of colorectal cancer:Possible mechanisms[J].J Cell Physiol,2019,234(3):2306-16. [4] SZOSTEK J,SERAFIN M,MĄKA M,et al.Right-Sided Versus Left-Sided Colon Cancer-A 5-Year Single-Center Observational Study[J]. Cancers(Basel),2025,17(3). [5] LI Q,SUN W,YUAN D,et al.Efficacy and safety of recombinant human tumor necrosis factor application for the treatment of malignant pleural effusion caused by lung cancer[J].Thorac Cancer,2016,7(1):136-9. [6] GHOLAMALIZADEH M,MIRZAEI DAHKA S,SEDIGH EBRAHIM-SARAIE H,et al.The Role of Tumor Necrosis Factor-α(TNF-α) Polymorphisms in Gastric Cancer:a Meta-Analysis[J].J Gastrointest Cancer,2022,53(3):756-69. [7] 李波,张雪伟,武文娟.重组改构人肿瘤坏死因子治疗直肠癌肝转移一例[J].临床肿瘤学杂志,2025,30(03):307-8. [8] SUN T,ZHU T,LIANG X,et al.Effects of Recombinant Circularly Permuted Tumor Necrosis Factor(TNF)-Related Apoptosis-Inducing Ligand(TRAIL)(Recombinant Mutant Human TRAIL)in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480[J].Med Sci Monit,2018,24:2550-61. [9] 中国医师协会结直肠肿瘤专业委员会.结直肠癌腹膜转移诊治中国专家共识(2025版)[J].实用肿瘤杂志,2025,40(03):193-202. [10] 中国医师协会结直肠肿瘤专业委员会腹膜肿瘤专委会.结直肠癌腹膜转移诊治中国专家共识(2022版)[J].中华结直肠疾病电子杂志,2022,11(04):265-71. [11] VAN GESTEL Y R,THOMASSEN I,LEMMENS V E,et al.Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer[J].Eur J Surg Oncol,2014,40(8):963-9. [12] FRANKO J,SHI Q,GOLDMAN C D,et al.Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy:a pooled analysis of north central cancer treatment group phaseⅢtrials N9741 and N9841[J].Journal of clinical oncology:official journal of the American Society of Clinical Oncology,2012,30(3):263-7. [13] 陈亚军,姜玉娟,周思成,等.重组改构人肿瘤坏死因子用于进展期结肠癌患者术中腹腔灌注治疗的近期安全性及可行性分析[J].中华结直肠疾病电子杂志,2024,13(02):94-100. [14] 张伟京,克晓燕,王杰军,等.注射用重组改构人肿瘤坏死因子-NC(rhTNF-NC)治疗恶性肿瘤的Ⅱ期临床研究[J].临床肿瘤学杂志,2015,20(09):819-24. [15] ROBERTS N J,ZHOU S,DIAZ L A,JR.,et al.Systemic use of tumor necrosis factor alpha as an anticancer agent[J].Oncotarget,2011, 2(10):739-51. [16] 秦叔逵,马军,李进,等.重组改构人肿瘤坏死因子治疗恶性胸､腹腔积液的临床应用专家共识[J].临床肿瘤学杂志,2018,23(01):67-72.

点击下载PDF